San Diego-based Nereus Pharmaceuticals has raised $42.6M in a Series D funding led by HBM BioVentures (Cayman) Ltd. and HBM BioCapital LP. New investors included Advent International, InterWest Partners, Genavent Partners (Sanofi-Aventis), and Red Abbey Venture Partnerse. Existing investors Alta Partners, Forward Ventures, GIMV, Novartis Bioventure Fund, Pacific Venture Group, FirstBio, and Lotus BioScience Ventures all participated. HBM Advisors, Advent, and Interwest all added representatives to the board. Nereus is focused on discovering anticancer compounds and anti-infectives. More information »